Speculation regarding poorer outcomes for those with high cholesterol and/or heart disease infected with SARS-CoV-2 are well known. A real-world study published by the FH Foundation confirms Covid-19 increased heart attack rates significantly in patients with these conditions. 

The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.

A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.

Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.

The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.

In a Reuters roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, common cold antibodies yield clues to Covid-19 behavior.

AstraZeneca’s Brilinta (ticagrelor) was approved by the U.S. Food and Drug Administration to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.

A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.